Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
NASDAQ:TGTX
TGTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.84 - $36.84
Previous CloseN/A
Volume723.16K
Average Volume (3M)2.21M
Market Cap
$4.85B
Enterprise Value$3.67B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.54
Next Earnings
Mar 04, 2025EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding155,665,330
10 Day Avg. Volume1,421,653
30 Day Avg. Volume2,213,205
Standard Deviation0.27
R-Squared0.20
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)18.32
Price to Cash Flow (P/CF)-99.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit16.76
Enterprise Value/Ebitda623.52
Forecast
1Y Price Target
$40.33Price Target Upside30.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
TG Therapeutics News
PremiumCompany Announcements
TG Therapeutics Reports Strong Revenue and Future Goals
---
Bulls Say, Bears Say
Bulls Say
Market AdoptionBriumvi has captured over 15% of new CD20 starts, demonstrating its competitive edge with a shorter chair time and no breast cancer risk warning compared to competitors.
Market Share PotentialBriumvi is projected to capture the majority share of the IV anti-CD20 market within five years.
Revenue GrowthTG Therapeutics reported strong 15% sequential growth in Briumvi U.S. sales, resulting in a 3Q beat.
Bears Say
Competitive PressuresHigher percentage of surveyed physicians consider switching Kesimpta to Ocrevus SQ rather than Briumvi to Ocrevus SQ.
Guidance AdjustmentThe 2025 estimate was slightly lowered to align with the company's guidance.
Metric Reporting ChangesTGTX's move away from reporting on TRx/NRx metrics contributed to a -10% intra-day equity weakness.
---
Ownership Overview
10.00% Insiders
16.35% Mutual Funds
11.95% Other Institutional Investors
36.99% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TGTX FAQ
What was TG Therapeutics’s price range in the past 12 months?
TG Therapeutics lowest stock price was $12.84 and its highest was $36.84 in the past 12 months.
What is TG Therapeutics’s market cap?
TG Therapeutics’s market cap is $4.85B.
When is TG Therapeutics’s upcoming earnings report date?
TG Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is in 11 days.
How were TG Therapeutics’s earnings last quarter?
TG Therapeutics released its earnings results on Nov 04, 2024. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by -$0.01.
Is TG Therapeutics overvalued?
According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
Does TG Therapeutics pay dividends?
TG Therapeutics does not currently pay dividends.
What is TG Therapeutics’s EPS estimate?
TG Therapeutics’s EPS estimate is 0.16.
How many shares outstanding does TG Therapeutics have?
TG Therapeutics has 155,665,330 shares outstanding.
What happened to TG Therapeutics’s price movement after its last earnings report?
TG Therapeutics reported an EPS of $0.02 in its last earnings report, missing expectations of $0.03. Following the earnings report the stock price went down -9.442%.
Which hedge fund is a major shareholder of TG Therapeutics?
Currently, no hedge funds are holding shares in TGTX
---
TG Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.33 (30.05% Upside)
$40.33 (30.05% Upside)
Blogger Sentiment
Bullish
TGTX Sentiment 90%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 64.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $629.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
124.22%
12-Months-Change
Fundamentals
Return on Equity
-8.05%
Trailing 12-Months
Asset Growth
77.01%
Trailing 12-Months
Company Description
TG Therapeutics
TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.
---
TGTX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive sentiment, driven by robust sales growth, promising clinical data, and strategic investments into expanding the commercial infrastructure and product pipeline. While there are slight market challenges and competitive considerations, the outlook remains highly optimistic.Read More>---
TGTX Stock 12 Month Forecast
Average Price Target
$40.33
▲(30.05% Upside)
Technical Analysis
Best Analysts Covering TGTX
1 Year
1 Year Success Rate
22/28 ratings generated profit
1 Year Average Return
+80.05%
reiterated a buy rating last month
Copying Edward White's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +80.05% per trade.
---